Monday, October 29, 2018
Resverlogix initiated with a Buy at Roth Capital
Resverlogix initiated with a Buy at Roth Capital. Roth Capital analyst Jotin Marango started with a Buy rating and C$10 price target. The analyst believes that the selective bromodomain inhibitor Apabetalone is the most clinically advanced, setting up an important pivotal readout in Q1 2019 for both Resverlogix and epigenetics at large.
https://thefly.com/landingPageNews.php?id=2812527
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.